When was Ultomiris approved by the FDA?

The U.S. Food and Drug Administration approved Ultomiris in April 2022 for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor. In addition to gMG, Ultomiris is approved in the U.S. for atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, and neuromyelitis optica spectrum disorder.